Many Korean pharmaceutical firms want to enter glimepiride market

Published: 2004-07-01 06:59:00

Updated: 2004-07-01 06:59:00

In coming autumn, Hadok-Aventis Pharma will face an uphill battle in trying to protect its glimepiride market from domestic competition as 33 generic items of Amaryl (glimepiride), an oral antidiabetic agent, received collective approvals from the Korea Food and Drug Administration on both June 2...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK